Fractyl Health, INC 8-K filings
NASDAQ
8-K: Fractyl Health Announces Positive Initial Results for Weight Maintenance After GLP-1 Discontinuation
Fractyl Health reports promising initial clinical results demonstrating weight maintenance following GLP-1 drug discontinuation and Revita procedure in the first patient of the REVEAL-1 cohort, along with strong enrollment progress for the REMAIN-1 weight maintenance pivotal study.
NASDAQ
Fractyl Health reported its third quarter 2024 financial results, highlighted progress in clinical trials, and provided updates on its Revita and Rejuva platforms.
NASDAQ
Fractyl Health has announced positive preclinical data for its Rejuva RJVA-001 gene therapy and nominated RJVA-002 as its lead candidate for obesity treatment.
NASDAQ
Fractyl Health reported its second quarter 2024 financial results, highlighted by positive clinical updates for its Revita and Rejuva programs, including a new FDA Breakthrough Device designation.
NASDAQ
Fractyl Health's Revita System has been granted Breakthrough Device Designation by the FDA for maintaining weight loss after discontinuation of GLP-1 drugs, with pivotal study data expected in late 2024 and mid 2025.
NASDAQ
Fractyl Health announces the acceleration of its REMAIN-1 weight maintenance study, expansion of its REVITALIZE-1 diabetes study, and positive preclinical data for its Rejuva gene therapy.
NASDAQ
Fractyl Health announced its first quarter 2024 financial results and provided updates on its clinical programs, including the initiation of a pivotal study for weight maintenance and anticipated topline data for a type 2 diabetes study.
NASDAQ
Fractyl Health reported its fourth quarter and full year 2023 financial results, highlighted by the IDE approval for a pivotal weight maintenance study and progress in their gene therapy platform.
NASDAQ
Fractyl Health has received FDA approval for its Investigational Device Exemption (IDE) to study Revita's effectiveness in maintaining weight loss after patients discontinue GLP-1 receptor agonist drug therapy.
NASDAQ
Fractyl Health, Inc. successfully closed its initial public offering, raising approximately $110 million, and implemented significant changes to its corporate governance structure.